Elekta的MLCI2 Multireaf准直器有助于在将高剂量的递送到靶标之间的细平衡,并将剂量减少到目标体积之外的健康组织。MLCI2,即使使用高级输送技术也是由Elekta完全集成的数字控制系统驱动的低积分剂量。
与非数字系统不同,信息传输没有滞后,确保所有叶子的连续验证和准确放置。这允许比非数字系统更快,更安全,更准确的交付。
The active leakage reduction mechanism in the Elekta MLCi2, uses diaphragms in both directions to automatically track the trailing leaf, thus reducing transmission. This feature plays a valuable role in reducing integral dose to the patient and therefore reducing the risk of induced secondary cancer.
At the forefront of clinical advancements, Elekta has been instrumental in delivering techniques like IGRT, IMRT, VMAT as well as SBRT and SRT. These techniques have given clinicians the flexibility to deliver conventional therapies to treat a wide range of tumors throughout the body, while also enabling treatment of highly complex cancers that require extreme targeting precision.